Centene Posts Higher Revenue and a Loss-to-Profit Swing on the Bottom Line for the Three-Month Reporting Period, with Year-to-Date Profitability Also Improving

Bottom line

For the three-month reporting period, Centene Corporation reported a profit on both the top line and the bottom line that moved higher than the prior-year comparative, including a loss-to-profit swing on Net Income (Loss) Attributable to Parent, Operating Income (Loss), and Earnings Per Share, Diluted. Revenue from Contract with Customer, Excluding Assessed Tax and the broader Revenues line both stepped up versus the prior-year quarter. For the six-month year-to-date period, the same top-line and bottom-line dimensions again came in higher than the prior-year comparative, with profit-to-profit movement on Net Income (Loss) Attributable to Parent, Operating Income (Loss), and Earnings Per Share, Diluted. No segment-level breakout accompanies these results in the filing evidence, and no peer or industry comparison is included alongside the filing.

The filing is identified as CENTENE CORP (CNC) filing 10-Q for period-ended-2026-06-30, with 0001071739 and 0001071739-26-000153 confirming the source. The quoted narrative accompanying the filing opens with the cautionary statement on forward-looking statements, framed around private-securities-litigation-reform-act safe-harbor language, and notes that the forward-looking discussion is cross-referenced to Item 1A. The narrative reiterates that statements about future operating or financial performance, contract start dates, pricing actions, completed and future acquisitions and dispositions, and the adequacy of cash resources are subject to risks and uncertainties and that actual results may differ materially. The filing evidence does not attribute the quarter-over-quarter and year-to-date movement to any single cause, so the underlying driver of the loss-to-profit swing on the three-month view and the higher year-to-date readings is left to the machine-owned note rather than narrated here.

A reader comparing this quarter's loss-to-profit swing on the bottom line against other recent interim filings can see a parallel pattern in AES Corp interim filing shows higher revenue and a loss-to-profit swing on net income and diluted EPS for both the quarter and the six-month year-to-date period, while capital and dividend outflows also stepped up, which mirrors the direction of movement on revenue, net income, and diluted EPS seen here, though the two issuers operate in different industries and the filing evidence contains no peer or industry comparison that would let this section draw a like-for-like benchmark.

Source scope is limited to the figures and narrative quoted from the filing itself. The filing evidence does not attribute this change to any single cause.

Financial performance

- The filing reports top-line growth alongside a clear bottom-line inflection on the three-month reporting period. Revenue from Contract with Customer, Excluding Assessed Tax moved higher than the prior-year comparative for both the three-month reporting period and the six-month year-to-date period, and the second revenue line item (Revenues) showed the same direction of change on both views. Higher top-line revenue does not by itself explain the swings in profitability below.

- Operating Income (Loss) returned to a profit on the three-month reporting period after reporting a loss in the prior-year comparative, and it also improved on the six-month year-to-date view versus the prior-year comparative. Net Income (Loss) Attributable to Parent followed the same pattern: a loss-to-profit swing on the three-month reporting period and an improvement on the six-month year-to-date basis. Earnings Per Share, Diluted also moved from a loss in the prior-year three-month comparative to a profit in the current three-month reporting period, and improved on the six-month year-to-date view. The improvement in profitability on the three-month reporting period therefore shows up consistently across the operating line, the bottom line, and the per-share line.

- On the six-month year-to-date view, the operating-income, net-income, and diluted-EPS comparisons are profit-to-profit improvements rather than a swing across zero, which is a different shape from the quarter-only results.

- The filing does not tie either the revenue gains or the profitability inflection to a single identified driver. The filing evidence does not attribute this change to any single cause.

- The forward-looking statements section enumerates a long list of risks that could affect future performance, including healthcare-cost and utilization volatility, regulatory and reimbursement changes, ACA-related items such as the Enhanced Advance Premium Tax Credits, CMS Star ratings, competition, and macroeconomic conditions. These are cautionary statements about future periods rather than explanations of the reported period's results.

- The filing evidence does not provide a quarter-over-quarter sequential comparison for the most recent three-month reporting period, because the comparative columns presented are the prior year rather than the immediately preceding quarter. The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for these dimensions. The filing evidence does not disclose segment-level detail for this dimension.

- No management guidance range for the next quarter or the full year is presented in the quoted material; the cautionary-statement passage is qualitative risk language, not forward financial targets.

- Readers cross-checking earnings comparing across recent filings can contrast this loss-to-profit pattern with the AES Corp interim filing, which also showed a loss-to-profit swing on net income and diluted EPS for both the quarter and the six-month year-to-date period, against a similar year-over-year increase in revenue.

Operating drivers and segments

- Reported revenue from contracts with customers, excluding assessed tax, was higher year over year for both the three-month reporting period and the six-month year-to-date period, at $44,375,000,000 versus $42,467,000,000 and $89,030,000,000 versus $84,956,000,000, respectively. - The filing’s broader revenues measure shows the same directional pattern: higher for the three-month reporting period and the six-month year-to-date period, at $53,579,000,000 versus $48,742,000,000 and $103,523,000,000 versus $103,523,000,000.

- Operating income was positive in the current three-month reporting period but negative in the corresponding prior-year period, at $1,198,000,000 versus -$458,000,000. For the six-month year-to-date view, operating income remained positive and increased year over year, at $3,059,000,000 versus $1,076,000,000. - Taken together, the evidence indicates that top-line growth coincided with stronger operating profitability, especially in the latest quarter, where the company moved from an operating loss to a profit.

The filing evidence does not provide a segment-level breakdown, operating margin series, or medical-cost trend that would support a more detailed assessment of which businesses or expense categories generated the improvement. - The company identifies Magellan Health’s remaining businesses as part of the Other segment and says it signed a definitive agreement to sell them. This confirms an ongoing portfolio action, but the evidence does not quantify its effect on current revenue, operating income, segment margins, or the holding-company perimeter.

The filing evidence contains no peer or industry comparison. - Management frames the forward-looking discussion around expected future operating and financial performance, pricing actions, competition, contract timing and terms, acquisitions and dispositions, investments, and the adequacy of available cash resources. It also identifies the ability to design and price competitive or actuarially sound products, manage health benefits and other operating expenses and reserves, and respond to medical-cost fluctuations as important considerations.

- The filing further highlights payment levels and timing from government payors, rate actions, state and federal funding for government-sponsored healthcare programs, economic conditions, and regulatory developments as factors that may affect future results. These statements describe management’s risk framework rather than establishing which factors produced the reported year-over-year changes. - The company also discusses prospective accounting guidance on income-statement expense disaggregation and changes to the threshold for capitalizing software costs.

That prospective disclosure is not evidence of a current operating driver and should not be treated as a retrospective explanation for revenue or operating-income performance. - Management’s forward-looking statements are expressly not guarantees of future performance and remain subject to known and unknown risks, uncertainties, and assumptions. Consequently, the reported revenue and operating-income improvements are verified against the prior-year comparative figures, but management’s broader expectations do not independently establish that those trends will continue.

The filing evidence does not attribute this change to any single cause.

Cash flow and capital

- For the six-month year-to-date period, Net Cash Provided by (Used in) Operating Activities was a positive inflow of $7,956,000,000 USD, compared with a positive inflow of $3,295,000,000 USD in the prior-year comparative the six months ended June 30, 2025 — an authorized year-over-year increase on a continuing-positive base. The cash proceeds from the receivable sale program and the associated loss on sale flow through operating activities per the cited note, tying working-capital mechanics to the operating line.

- Net Cash Provided by (Used in) Investing Activities was a cash outflow of -$264,000,000 USD for the six months ended June 30, 2026, versus an outflow of -$1,428,000,000 USD for the six months ended June 30, 2025 — an authorized year-over-year increase in the outflow (i.e., a smaller negative number than the prior period). Capital spending shows up here: Payments to Acquire Property, Plant, and Equipment were $374,000,000 USD for the current half-year and $343,000,000 USD for the prior-year half-year, an authorized year-over-year increase.

- Net Cash Provided by (Used in) Financing Activities was a cash outflow of -$1,322,000,000 USD for the six months ended June 30, 2026, against an outflow of -$1,424,000,000 USD for the six months ended June 30, 2025 — an authorized year-over-year increase on a continuing-negative base. Share repurchases appear within financing: Payments for Repurchase of Common Stock were $33,000,000 USD for the current half-year versus $473,000,000 USD in the prior-year half-year, an authorized year-over-year decrease. The filing evidence does not attribute this change to any single cause.

Reported facts: - The balance sheet at the balance sheet date of June 30, 2026 carried Cash and Cash Equivalents, at Carrying Value of $24,151,000,000 USD and Long-term Debt, Excluding Current Maturities of $16,030,000,000 USD. - Items that framed the period's cash story but sit outside the three cash-flow statements include the signed definitive agreement to sell the remaining Magellan Health businesses (reported within the Other segment) and the resulting held-for-sale reclassification on the consolidated balance sheet, plus the master receivable purchase agreement referenced in the cited note.

Management explanations: - Management describes the interim statements as reflecting normal recurring adjustments only, with footnote disclosures substantially duplicating the December (omitted) audited statements omitted where appropriate. Certain prior-period amounts were reclassified to conform to the current presentation, with no effect on net earnings or stockholders' equity. Management also notes that payments received in the second quarter of (omitted) will be passed through to recipients primarily during the third quarter, a timing disclosure that affects reported operating cash inflows without changing underlying earnings. - On the receivable program, management explains that eligible stand-alone Part D risk-sharing amounts are sold under a master receivable purchase agreement, with proceeds and the loss on sale recorded as operating cash flows. Receivables sold are derecognized from the balance sheet, and the agreement is without recourse for CMS credit losses.

Analyst inference: - The authorized directional patterns describe a setup in which operating cash generation strengthened year over year while investing and financing cash outflows both moderated in magnitude — i.e., the company used less cash for both capital projects and financing transactions than in the prior comparative half-year, even as buyback spending stepped down. The period's reported balance-sheet figures provide the headline liquidity-versus-leverage anchors, and the receivable-sale program offers one structural link between working-capital timing and the operating line.

Counter-evidence / cross-checks: - The cash-flow pattern is internally consistent with the cited disclosure that receivable-sale proceeds and the associated loss on sale flow through operating activities; nothing in the catalog contradicts the directional pattern. - The filing evidence contains no peer or industry comparison.

Unknowns: - The specific drivers behind the year-over-year shifts in operating, investing, and financing cash flows, including the buyback step-down and the higher capital expenditures, are not attributed by the filing. The filing evidence does not attribute this change to any single cause. - The composition of Long-term Debt, Excluding Current Maturities at the balance sheet date of June 30, 2026 — instrument mix, maturity profile, and any new issuance or repayment detail — is not surfaced in this section's catalog and is therefore not addressed here.

Peer and historical context

This section holds the filing for CENTENE CORP (CNC) on 10-Q for period-ended-2026-06-30, filed under accession 0001071739-26-000153, up against its own prior-year comparative windows rather than against any external peer set.

Reported facts drawn from the consolidated statements for CENTENE CORP show that the top line expanded on both comparison windows. Revenue from Contract with Customer, Excluding Assessed Tax was $42,467,000,000 USD for the three months ended June 30, 2025 and $44,375,000,000 USD for the three months ended June 30, 2026, a higher reading against the prior-year quarter. The six-month year-to-date measure was $84,956,000,000 USD for the six months ended June 30, 2025 and $89,030,000,000 USD for the six months ended June 30, 2026, again higher than the prior-year comparative. A second revenue caption, simply labelled Revenues, was $48,742,000,000 USD for the three months ended June 30, 2025 versus $53,579,000,000 USD for the three months ended June 30, 2026, and $95,362,000,000 USD for the six months ended June 30, 2025 versus $103,523,000,000 USD for the six months ended June 30, 2026 — the authorized direction on both captions is an increase year over year on the quarter and on the six-month view.

The bottom line also moved higher in a manner that is unusual for a quarter-over-quarter comparison. Operating Income (Loss) was -$458,000,000 USD for the three months ended June 30, 2025 — a loss — and $1,198,000,000 USD for the three months ended June 30, 2026, a profit, producing an authorized loss-to-profit swing. On the six-month year-to-date view, Operating Income (Loss) was $1,076,000,000 USD for the six months ended June 30, 2025 and $3,059,000,000 USD for the six months ended June 30, 2026, staying in profit territory and stepping higher. Net Income (Loss) Attributable to Parent tracked the same pattern: -$253,000,000 USD for the three months ended June 30, 2025 (a loss) versus $1,091,000,000 USD for the three months ended June 30, 2026 (a profit), again an authorized loss-to-profit transition, while the six-month view held in profit at $1,058,000,000 USD for the six months ended June 30, 2025 rising to $2,632,000,000 USD for the six months ended June 30, 2026.

Cash generation from the operating activities line was $3,295,000,000 USD for the six months ended June 30, 2025 and $7,956,000,000 USD for the six months ended June 30, 2026, an authorized increase that stays positive on both sides. Reading across these comparisons, CENTENE CORP delivered higher revenue, higher operating income, higher net income and higher operating cash on the six-month view, and it converted a prior-year quarterly loss into a profit on both operating income and net income — a clean loss-to-profit transition rather than a marginal improvement.

Management commentary in the filing discusses the disposition of the remaining Magellan Health businesses, the accounting treatment of those assets and liabilities as held for sale, and the February receivable purchase agreement under which the Company sold Part D risk-sharing receivables, with proceeds applied to the partial redemption of Senior Notes. Those narratives sit alongside, not inside, the year-over-year comparisons above, so the driver of any specific gap is The filing evidence does not attribute this change to any single cause..

Peer benchmarking is not part of this filing; no peer or industry comparable is presented inside the document, so any cross-issuer read falls outside what is evidenced here. A contemporaneous quarterly read on a non-healthcare issuer is available in SMITH A O CORP (AOS) Reports Softer Revenue, Operating Income, Net Income, and Diluted EPS on Both the Quarter and Six-Month Year-to-Date Views in Form (Accession, which moves in the opposite direction and helps frame how unusual the loss-to-profit swing on the three months ended June 30, 2026 is for CENTENE CORP.

The filing evidence does not attribute this change to any single cause.

Scenario analysis

- Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax moved higher on both the three-month reporting period and the six-month year-to-date period, comparing the three months ended June 30, 2025 to the three months ended June 30, 2026 and the six months ended June 30, 2025 to the six months ended June 30, 2026, with the current-period readings at $44,375,000,000 USD and $89,030,000,000 USD versus the prior-period readings at $42,467,000,000 USD and $84,956,000,000 USD. The Revenues line item followed the same directional pattern, with the current quarter at $53,579,000,000 USD, the current year-to-date at $103,523,000,000 USD, and the prior-period comparators at $48,742,000,000 USD and $95,362,000,000 USD. Net Income (Loss) Attributable to Parent was a profit of $1,091,000,000 USD for the three-month reporting period, compared with a loss of -$253,000,000 USD a year earlier, and was a profit of $2,632,000,000 USD for the six-month year-to-date period versus $1,058,000,000 USD in the prior-year span. - Management explanations: The cautionary language and exhibit list live in Item 6 and the controls and procedures discussion sits in Item 4; legal proceedings appear under Item 1 and risk factors under Item 1A, while other information appears under Item 2. The filing also describes Magellan Health being held for sale in the Other segment and a February receivable purchase agreement tied to CMS Part D risk-sharing programs. - Analyst inference: The revenue lines and the net income line both pointed in the same direction across the quarter and the year-to-date view, and the quarter swung from a loss to a profit on the bottom line. - Counter-evidence: The filing evidence contains no peer or industry comparison. - Unknowns: The filing evidence does not attribute this change to any single cause.

- Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax rose to $44,375,000,000 USD in the three months ended June 30, 2026 from $42,467,000,000 USD in the three months ended June 30, 2025, and to $89,030,000,000 USD in the six months ended June 30, 2026 from $84,956,000,000 USD in the six months ended June 30, 2025. The Revenues line corroborated the move, with $53,579,000,000 USD and $103,523,000,000 USD versus $48,742,000,000 USD and $95,362,000,000 USD. Net Income (Loss) Attributable to Parent reached $1,091,000,000 USD in the quarter versus a loss of -$253,000,000 USD, and reached $2,632,000,000 USD in the year-to-date versus $1,058,000,000 USD. - Management explanations: The disclosed Magellan Health sale and the February receivable purchase agreement point to ongoing portfolio reshaping and balance-sheet management. - Analyst inference: A higher top line alongside a loss-to-profit swing on the bottom line in the quarter is consistent with the upside framing in this section. - Counter-evidence: The filing evidence contains no peer or industry comparison. - Unknowns: The filing evidence does not attribute this change to any single cause.

- Reported facts: On the downside path, the same revenue and net income figures describe a frame in which contract revenue of $44,375,000,000 USD and $89,030,000,000 USD could be tested against prior-period readings of $42,467,000,000 USD and $84,956,000,000 USD, and Revenues of $53,579,000,000 USD and $103,523,000,000 USD could be tested against $48,742,000,000 USD and $95,362,000,000 USD. The bottom-line swing from a loss of -$253,000,000 USD to a profit of $1,091,000,000 USD in the quarter, and the year-to-date move from $1,058,000,000 USD to $2,632,000,000 USD, would be the metrics most exposed if conditions reversed. - Management explanations: Risk factors appearing under Item 1A frame the cautionary boundary conditions that an investor might map onto this downside case. - Analyst inference: The downside scenario is anchored to the same reported lines, read as potential stress points rather than drivers. - Counter-evidence: The filing evidence contains no peer or industry comparison. - Unknowns: The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- The most notable swing in the bottom line is on the three-month view, where Net Income (Loss) Attributable to Parent moved from a loss in the prior-year period to a profit in the current period. On the six-month year-to-date view, Net Income (Loss) Attributable to Parent remained profitable and improved in direction. The reversal on the quarter is the headline change, and any drift back toward a loss would be the clearest risk signal for the next filing.

- Top-line growth is confirmed on both measures: Revenue from Contract with Customer, Excluding Assessed Tax rose on the quarter and the six-month year-to-date views, and the broader Revenues line rose on the same comparisons. The directional pattern is positive on both lines and both periods. The risk to monitor is whether the top-line gain continues to flow through to the bottom line, since the gap between revenue direction and net income direction can narrow if cost pressure intensifies.

The filing evidence does not attribute this change to any single cause. - The filing discloses a receivable purchase agreement tied to stand-alone Part D risk-sharing programs, with recourse limited to the financial condition of CMS. Because the structure is without recourse for CMS credit losses, this counterparty channel is a structural exposure worth flagging for the next period.

Any change to the maximum outstanding purchase amount, the SOFR-based discount spread, or the servicing-fee assessment would be material. - Proceeds from the receivable sale were used to partially redeem Senior Notes due in a later year, linking an operating-cash transaction to liability management. The next filing should disclose the residual redemption balance and any gain or loss on extinguishment, both of which are unstated here.

- Sold receivables are derecognized, and the difference between carrying amount and cash proceeds is recorded as a loss on sale inside selling, general and administrative expenses. That loss sits within operating expenses and can quietly pressure operating income even as revenue rises, so the next period's selling, general and administrative expense line deserves close reading relative to revenue. - Counter-evidence to the profit rebound is limited inside this filing because segment-level detail for the swing is not disclosed here.

The filing evidence does not disclose segment-level detail for this dimension. - Peer or industry comparison is not provided in the filing evidence, so the magnitude of the bottom-line improvement cannot be benchmarked against other health plans in this section. The filing evidence contains no peer or industry comparison.

- For directional context on how comparable loss-to-profit reversals have read in the same reporting window, the AES Corp interim filing shows higher revenue and a loss-to-profit swing on net income and diluted EPS article illustrates a similar pattern. - Unknowns to flag for the next period: the servicing fee and cost-of-servicing assumptions behind the receivable sale, any change in the SOFR spread affecting future purchase discounts, the residual balance on the redeemed Senior Notes, and whether the receivable sale program is expanded, renewed, or repriced.

- Metrics to watch next period: revenue direction on both the contract and total lines, the loss-or-profit status of the quarterly net income line, the trend in selling, general and administrative expense relative to revenue, the operating cash flow treatment of any further receivable sales, and any update to the receivable purchase maximum or redemption progress.